ASC22 (Envafolimab) is a subcutaneously administered single-domain antibody against PD-L1 and has the potential to restore virus-specific immune responses in patients with chronic viral infection
The company intends to begin using drones to make deliveries of critical and emergency medical supplies, vaccines, and lifesaving drugs after getting the prerequisite regulatory approvals
The funding will enable the company to expand into the segment of HealthCare Service offerings, both in terms of geography and operations
HK inno.N Corporation will be responsible for the manufacture and supply of Tegoprazan, while Dr. Reddy's will handle local clinical development, registration, marketing and sales
The new logo is a refreshing change from the version that has served Hetero well for three decades. And yet its reflection can be seen in the new version
Nirsevimab is the first investigational immunization designed to protect all infants across the RSV season with a single dose
Company's net income rose by 57.5 percent to 3.291 billion euros in Q1
Bora establishes a leadership position in Taiwan's CDMO sector as it continues to expand into the global CDMO market
CEPI will provide funding of up to US $19.3 million to support the development of a ‘variant-proof’ SARS-CoV-2 vaccine candidate to an international multidisciplinary consortium
The capex for FY22 stood at Rs 145 crore and is expected to be in the range of Rs 250-350 crore for the entire FY23 which would be funded through a mix of internal accruals and debt
Subscribe To Our Newsletter & Stay Updated
